Strides Shasun’s wholly owned subsidiary -- Strides Pharma Global has received approval for Cyproheptadine Hydrochloride Tablets USP, 4 mg from the United States Food & Drug Administration (USFDA). Cyproheptadine Hydrochloride Tablets is a generic version of Periactin Tablets of Merck & Co. Inc.
According to IQVIA data, the US market for Cyproheptadine Hydrochloride Tablets USP, 4 mg is approximately $20 million. The product will be manufactured at the company’s Oral dosage facility at Bangalore and will be marketed by Strides Pharma in the US Market. The company has 74 cumulative ANDA filings with USFDA of which 46 ANDAs have been approved as of date and 28 are pending approval.
Strides Shasun is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The company has 74 cumulative ANDA filings with USFDA of which 45 ANDAs have been approved as of date and 29 are pending approval.
